Arming NK cells with enhanced antitumor activity: CARs and beyond

Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberoi, Pranav, Wels, Winfried S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805653/
https://www.ncbi.nlm.nih.gov/pubmed/24167761
http://dx.doi.org/10.4161/onci.25220
_version_ 1782477896242167808
author Oberoi, Pranav
Wels, Winfried S
author_facet Oberoi, Pranav
Wels, Winfried S
author_sort Oberoi, Pranav
collection PubMed
description Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laboratory suggest that NK cells may similarly be “armed” against neoplastic cells by the expression of cancer-specific granzyme B-containing fusion proteins that are released as soluble factors upon NK-cell activation.
format Online
Article
Text
id pubmed-3805653
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38056532013-10-28 Arming NK cells with enhanced antitumor activity: CARs and beyond Oberoi, Pranav Wels, Winfried S Oncoimmunology Author's View Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laboratory suggest that NK cells may similarly be “armed” against neoplastic cells by the expression of cancer-specific granzyme B-containing fusion proteins that are released as soluble factors upon NK-cell activation. Landes Bioscience 2013-08-01 2013-06-10 /pmc/articles/PMC3805653/ /pubmed/24167761 http://dx.doi.org/10.4161/onci.25220 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Oberoi, Pranav
Wels, Winfried S
Arming NK cells with enhanced antitumor activity: CARs and beyond
title Arming NK cells with enhanced antitumor activity: CARs and beyond
title_full Arming NK cells with enhanced antitumor activity: CARs and beyond
title_fullStr Arming NK cells with enhanced antitumor activity: CARs and beyond
title_full_unstemmed Arming NK cells with enhanced antitumor activity: CARs and beyond
title_short Arming NK cells with enhanced antitumor activity: CARs and beyond
title_sort arming nk cells with enhanced antitumor activity: cars and beyond
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805653/
https://www.ncbi.nlm.nih.gov/pubmed/24167761
http://dx.doi.org/10.4161/onci.25220
work_keys_str_mv AT oberoipranav armingnkcellswithenhancedantitumoractivitycarsandbeyond
AT welswinfrieds armingnkcellswithenhancedantitumoractivitycarsandbeyond

Ejemplares similares